Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women

Lowe, Julia
September 2002
ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41
Academic Journal
Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable outcomes of estrogen plus progestin.


Related Articles

  • Hormone replacement therapy preparations. Sturdee, David W. // Journal of the British Menopause Society;2000, Vol. 6 Issue 1, p34 

    The article reports on licensed hormone replacement therapy regimens in Great Britain. The most suitable initial treatment for 80 percent of women is oral estrogen. About 15 percent of women have transdermal estrogen. For over 50 years, pellets of crystallized estradiol have been available for...

  • Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Richard L. Tannen; Mark G. Weiner; Dawei Xie; Kurt Barnhart // Human Reproduction;Jun2007, Vol. 22 Issue 6, p1769 

    BACKGROUND In the Womens Health Initiative Randomized Controlled Trial (WHI RCT), estrogen-only treatment compared with combined estrogen–progestin treatment resulted in less coronary artery disease, no increase in breast cancer and no reduction in colorectal cancer. Since we...

  • Monophasic Estrogen-Progestogen Therapy and Sexuality in Postmenopausal Women. Fonseca, A. M.; Bagnoli, V. R.; Penteado, S. R. L.; Paixão, J. S.; Cavalcanti, A. L.; Pinotti, J. A. // Clinical Drug Investigation;2007, Vol. 27 Issue 2, p131 

    OBJECTIVE: This study aimed to evaluate the effects of monophasic estrogen-progestogen therapy on the sexuality and climacteric symptoms of postmenopausal women. PATIENTS AND METHODS: A prospective, randomised, double-blind, crossover, placebo-controlled, single-centre study was carried out...

  • Menopause Management Selected Updates and Clinical Issues. Hudson, Tori // Townsend Letter;Feb/Mar2006, Issue 271/272, p146 

    The article offers information about menopause management. Postmenopausal women who discontinued estrogen-progestogen therapy are significantly more likely to experience recurrence of their hot flashes and nightsweats. Botanical and nutrient topical products are now existing to enhance female...

  • Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p60 

    This article discusses whether estrogen plus progestin (EPP) is more effective than placebo for improving health-related quality of life in post-menopausal women. Women were allocated to EPP therapy. Improvement from baseline in physical functioning, bodily pain, and sleep disturbance was...

  • Progestin found vital in hormone replacement therapy. Dickinson, Ben // Drug Topics;3/4/96, Vol. 140 Issue 5, p64 

    Highlights the findings of a study concerning the use of conjugated equine estrogen (CEE) for hormone replacement therapy in postmenopausal women. Endometriums of women who enrolled in a postmenopausal estrogen-progestin interventions trial; Effects of estrogen with or without a progestin on...

  • Alzheimer’s disease: the impact of age-related changes in reproductive hormones. Simpkins, J. W.; Yang, S.-H.; Wen, Y.; Singh, M. // Cellular & Molecular Life Sciences;Feb2005, Vol. 62 Issue 3, p271 

    Two classes of ovarian steroids, estrogens and progestins, are potent in protecting neurons against acute toxic events as well as chronic neurodegeneration. Herein we review the evidence for neuroprotection by both classes of steroids, provide plausible mechanisms for these potent...

  • Trisequens.  // Royal Society of Medicine: Medicines;2002, p550 

    The article presents information on trisequens, a proprietary, prescription-only compound preparation of the estrogen estradiol and the progestogen norethisterone. Trisequens can be used to treat menopausal problems and also for osteoporosis prevention. It is available in tablet form.

  • Second long term HRT trial stopped early. White, Caroline // BMJ: British Medical Journal (International Edition);11/2/2002, Vol. 325 Issue 7371, p987 

    Reports that a trial that examined the long-term effects of hormone replacement therapy (HRT) was stopped early by the UK Medical Research Council. Reasons that the trial was halted; Cost of the study; Specifics of the study, which investigated the long-term effects of progestogen and of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics